129 related articles for article (PubMed ID: 2258083)
1. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
5. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
8. Effect of intracavitary radiotherapy on tumor-associated trypsin inhibitor (TATI) in patients with cervical and endometrial cancer.
Lehtovirta P; Turpeinen U; Stenman UH
Gynecol Oncol; 1990 Jul; 38(1):110-3. PubMed ID: 2354815
[TBL] [Abstract][Full Text] [Related]
9. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics.
Duk JM; De Bruijn HW; Groenier KH; Fleuren GJ; Aalders JG
Cancer; 1990 Apr; 65(8):1830-7. PubMed ID: 2317761
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
14. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI.
Kozakiewicz B; Chądzyńska M; Dmoch-Gajzlerska E; Stefaniak M
Tumour Biol; 2016 Jul; 37(7):9367-74. PubMed ID: 26779635
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response.
Leminen A; Alftan H; Stenman UH; Lehtovirta P
Acta Obstet Gynecol Scand; 1992 May; 71(4):293-7. PubMed ID: 1322623
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
18. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
Masson P; Pålsson B; Andren-Sandberg A
Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
